Siklos Hydroxyurea is the first and only FDA-approved hydroxyurea-based treatment for both adult and pediatric patients with sickle cell anemia. It is indicated to reduce the frequency of painful crises and the need for blood transfusions in patients 2 years of age and older with recurrent moderate to severe painful crises. Siklos offers body-weight adjusted dosing and can be dissolved in water for oral administration, making it a convenient option for patients.
Siklos is a safe and effective treatment option for both children and adults with sickle cell disease. It allows for flexible dosing based on body weight, blood count, and clinical response, and can be broken into smaller parts for precise dosing adjustments. By increasing the concentration of fetal hemoglobin, Siklos helps minimize the clinical severity of sickle cell disease and reduces the risk of vaso-occlusive complications and organ damage. With its unique pediatric indication and proven clinical experience, Siklos is a valuable choice for patients seeking to manage the symptoms and complications of sickle cell anemia.
Generated from the website